Top Markets
Coin of the day
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Rank in Stocks #30838
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Share Price
$0.089
Last synced: 2026-08-17
Market Cap
$15.36M
Change (1 day)
50.59%
Change (1 year)
111.85%
Country
US
Trade Inhibitor Therapeutics, Inc. (INTI)

Category

Number of shares outstanding for Inhibitor Therapeutics, Inc. (INTI)
Number of shares outstanding as of August 2026: 0
According to Inhibitor Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Inhibitor Therapeutics, Inc. (INTI) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
483.58M -
AU
- -
CH
0.00 -
BE